Esperion Therapeutics (ESPR) Shares Outstanding (Diluted Average) (2018 - 2026)

Esperion Therapeutics has reported Shares Outstanding (Diluted Average) for 9 years, with the latest figure at $251.4 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Diluted Average) rose 28.16% year-over-year to $251.4 million; the trailing twelve-month figure through Mar 2026 stood at $251.4 million (up 28.16% YoY), and the FY2025 full-year result was $207.9 million, up 11.05% from the prior year.
• Shares Outstanding (Diluted Average) for Q1 2026 stood at $251.4 million, up from $207.9 million in the prior quarter.
• The five-year high for Shares Outstanding (Diluted Average) was $251.4 million in Q1 2026, with the low at $61.0 million in Q1 2022.
• Historically, Shares Outstanding (Diluted Average) has averaged $144.5 million across 5 years, with a median of $184.4 million in 2024.
• Annual changes were most pronounced in 2022 — Shares Outstanding (Diluted Average) surged 144.12% — and 2025, when it increased 3.42%.
• Esperion Therapeutics' Shares Outstanding (Diluted Average) stood at $66.4 million in 2022, then surged by 55.26% to $103.1 million in 2023, then jumped by 81.54% to $187.2 million in 2024, then advanced by 11.05% to $207.9 million in 2025, then advanced by 20.92% to $251.4 million in 2026.
• The last three Shares Outstanding (Diluted Average) figures came in at $251.4 million (Q1 2026), $207.9 million (Q4 2025), and $198.2 million (Q3 2025), per Business Quant data.